[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Narfström et al., 2003 - Google Patents

Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog

Narfström et al., 2003

View HTML
Document ID
16301752934002768578
Author
Narfström K
Katz M
Bragadottir R
Seeliger M
Boulanger A
Redmond T
Caro L
Lai C
Rakoczy P
Publication year
Publication venue
Investigative ophthalmology & visual science

External Links

Snippet

purpose. To assess the efficacy of AAV-mediated gene therapy to restore vision in a large number of RPE65−/− dogs and to determine whether systemic and local side effects are caused by the treatment. methods. Normal RPE65 dog cDNA was subcloned into an rAAV …
Continue reading at arvojournals.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo

Similar Documents

Publication Publication Date Title
Narfström et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Boye et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod-and cone-specific expression in the primate retina
Boye et al. Highly efficient delivery of adeno-associated viral vectors to the primate retina
Dudus et al. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Jacobson et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis
Bush et al. Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: dose-dependent expression and improved retinal structure and function
Testa et al. Evaluation of Italian patients with leber congenital amaurosis due to AIPL1 mutations highlights the potential applicability of gene therapy
JP2017510296A (en) Compositions and methods for enhanced gene expression in cone cells
Borrás et al. Gene therapy for glaucoma: treating a multifaceted, chronic disease
Teo et al. Surgical removal of internal limiting membrane and layering of AAV vector on the retina under air enhances gene transfection in a nonhuman primate
Dufour et al. Toxicity and efficacy evaluation of an adeno-associated virus vector expressing codon-optimized RPGR delivered by subretinal injection in a canine model of X-linked retinitis pigmentosa
Martin et al. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene
Kreppel et al. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector
CN116113702A (en) Fusion protein and application thereof
Mansouri X-linked retinitis pigmentosa gene therapy: preclinical aspects
Chekuri et al. Long-term effects of gene therapy in a novel mouse model of human MFRP-associated retinopathy
US20220249700A1 (en) Polymer-based implant for retinal therapy and methods of making and using the same
US20230139443A1 (en) Treating autosomal dominant bestrophinopathies and methods for evaluating same
JP2021512912A (en) Viral vector transduction
US11541072B2 (en) AAV-CRISPR/Cas9 genome editing of VEGFR2 for treating ocular diseases
Mohanty et al. Safety of intravitreally delivered AAV2 vector‐mediated multi‐characteristic opsin genetic construct in wild type beagle dogs
Brown et al. Expression of NMNAT1 in the Photoreceptors is Sufficient to Prevent NMNAT1-Associated Disease
Baez et al. Inner limiting Membrane Peel Extends In vivo Calcium Imaging of Retinal Ganglion Cell Activity Beyond the Fovea in Non-Human Primate
EP4396344A1 (en) Methods for evaluating treatments for bestrophinopathies
Aguirre et al. The use of canine models to develop translational gene therapies for the treatment of six forms of inheritedretinal degenerationsb (Work conducted at the University of Pennsylvania-USA)